MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Myoclonus and Encephalitis as an Adverse Event of mRNA COVID-19 Vaccine

A. Kim, N. Kim, Y. Ju, Y. Jeon, SJ. Park (Cheongju, Republic of Korea)

Meeting: 2024 International Congress

Abstract Number: 1374

Keywords: Myoclonus: Clinical features

Category: Dystonia: Clinical Trials and Therapy

Objective: We aim to report a case of myoclonus as an adverse event mRNA COVID-19 vaccine.

Background: There have been multiple reports of neurological adverse event possibly caused by the COVID-19 vaccine, but establishing a clear connection in numerous instances is challenging. Herein, we report a case with myoclonus manifested following the COVID-19 vaccine with evident encephalitis on the brain imaging.

Method: We retrospectively reviewed medical charts and brain magnetic resonance imaging(MRI).

Results: A 54-year-old woman visited the hospital, complaining of myoclonus and numbness in her left arm. The patient had bronchiectasis two years ago and it was controlled well. She received the fourth Pfizer mRNA Covid-19 vaccination 3 weeks ago. About a week after vaccination, a tingling sensation occurred on the lateral side of the left elbow, and three days later, there was intermittent clonic movement at approximately 1Hz in the left upper arm. On the next day, numbness occurred in the left ankle and hip. The clonic movement was also developed in the right limbs. On the neurological examination, left shoulder myoclonus with slow velocity was observed. Twitching of the both shoulders and left leg occurred when the patient lifted the left arm.

Her brain MRI showed a high signal intensity on T2 imaging with enhancement in the right insula and frontal cortex. [Figure 1] The electroencephalogram and laboratory findings including COVID-19, paraneoplastic antibodies, herpes simplex virus polymerase chain reaction in cerebrospinal fluid were normal.

She was treated with levetiracetam 500mg twice a day and her myoclonus improved in part. Intravenous methylprednisolone was followed for the next 5 days, and her symptoms were completely resolved. Three weeks after discharge, her brain MRI showed that the right insula and frontal cortex lesion had almost disappeared.[Figure 2]

Conclusion: Since the outbreak of COVID-19, movement disorders related to COVID-19 or the COVID-19 vaccine have been reported. In most reported cases, they improved spontaneously or a result of immunotherapy such as steroid, IVIG, or plasmapheresis. Although the patient in the recent case did not have any symptoms suggestive of encephalitis, such as decreased consciousness or disorientation, we concluded her symptom was triggered by the COVID-19 vaccine. Her paresthesia and myoclonus developed 1 week after vaccination, and the encephalitis found on brain MRI.

References: HR Shun et al. Autoimmune Encephalitis as an Adverse Event of COVID-19 Vaccination. J Clin Neurol. 2022 Jan;18(1):114-116.

To cite this abstract in AMA style:

A. Kim, N. Kim, Y. Ju, Y. Jeon, SJ. Park. Myoclonus and Encephalitis as an Adverse Event of mRNA COVID-19 Vaccine [abstract]. Mov Disord. 2024; 39 (suppl 1). https://www.mdsabstracts.org/abstract/myoclonus-and-encephalitis-as-an-adverse-event-of-mrna-covid-19-vaccine/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2024 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/myoclonus-and-encephalitis-as-an-adverse-event-of-mrna-covid-19-vaccine/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley